They are classified as glucagon-like peptide 1 (GLP-1) agonists and, in addition to diabetes treatment, also demonstrate ...

The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Lilly has scored a major victory in its battle for the US diabetes drug market after a trial showed its Trulicity cut risk of cardiovascular events, even in patients who had no prior history of ...

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist tirzepat ...

Trulicity is another type of GLP-1 receptor agonist that is effective for reducing blood sugar levels and heart disease risk in people with diabetes. Like Ozempic, it’s an injectable medication ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...